We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+90.99%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$208M
AUM Growth
+$56.3M
Cap. Flow
-$4.69M
Cap. Flow %
-2.26%
Top 10 Hldgs %
97.46%
Holding
16
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$101M 48.41%
6,068,125
– –
BMEA icon
2
Biomea Fusion
BMEA
$84.6M
$24.8M 11.92%
798,757
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$22.4M 10.78%
1,115,352
-217,133
-16% -$4.69M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.69B
$21.6M 10.42%
1,025,000
– –
GLUE icon
5
Monte Rosa Therapeutics
GLUE
$1.4B
$11.5M 5.52%
1,472,331
– –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$5.39M 2.59%
2,834,910
– –
OKUR
7
OnKure Therapeutics
OKUR
$154M
$5.3M 2.55%
88,608
– –
NUVB icon
8
Nuvation Bio
NUVB
$2.2B
$4.22M 2.03%
2,541,009
– –
ACRS icon
9
Aclaris Therapeutics
ACRS
$726M
$3.51M 1.69%
434,455
– –
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.21M 1.55%
1,043,267
– –
SPRB
11
Spruce Biosciences
SPRB
$118M
$2.66M 1.28%
16,073
– –
TECX
12
Tectonic Therapeutic
TECX
$529M
$1.01M 0.49%
84,148
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$8.54B
$490K 0.24%
67,646
– –
VIRX
14
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$459K 0.22%
288,571
– –
BCEL
15
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$442K 0.21%
387,653
– –
MRKR icon
16
Marker Therapeutics
MRKR
$18.8M
$223K 0.11%
314,286
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Aisling Capital Management held 16 positions worth $208M, up 37% from $151M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 16-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q1 2023 reduction was Verona Pharma, cutting an estimated $4.69M.
  • Aisling Capital Management's ten largest holdings make up 97% of its $208M portfolio in Q1 2023.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q1 2023.
  • Aisling Capital Management's portfolio value rose 37% quarter-over-quarter to $208M.

Based on Aisling Capital Management's 13F filing for Q1 2023, filed 9 May 2023.